Our Foundation

We are a non-profit organisation recognised by the Italian Ministry of Education, Universities and Research. We were founded in 1990 in response to calls by people suffering from rare diseases.

Right from the start, we have always listened to patients, to provide the answers they need. Every day.

We manage fund raising activities and guarantee the necessary resources for our research projects. These projects are subjected to rigorous assessments on the part of an independent, international Scientific and Medical Committee.

Our Board of Directors

  • Luca di Montezemolo (Presidente)
  • Omero Toso (Vice presidente)
  • Francesca Pasinelli (Direttore Generale)
  • Alberto Fontana
  • Isabella Seragnoli
  • Giovanni Manfredi
  • Andrea Munari
  • Lupo Rattazzi
  • Carlo Pontecorvo
  • Fabio Gallia
  • Alessandra Colonna

How we fund research

Research funds are assigned throught the help of:

Scientific and Medical Committee: follows the peer-review procedure. Before the plenary discussion, each proposed project is examined by three committee members and at least two external reviewers selected from the international community. Thanks to this process, we can be sure that only the best projects are chosen.

Scientific Steering Committee: the task of the Scientific Steering Committee is to support the overall policy and management decisions of the Board of Directors within the framework of biomedical research. The Scientific Steering Committee composition is the following:

  • Virginie Bros-Facer, EURORDIS-Rare Diseases Europe (Paris, France)
  • Bev Holmes, Michael Smith Foundation for Health Research (Vancouver, Canada)
  • Naomi Taylor,  Institute of Molecular Genetics of Montpellier (Montpellier, France) and National Human Genome Research Institute, NIH (Bethesda, MD - USA)
  • Leonard Bell, Alexion Pharmaceuticals (Boston, MA - USA)
  • Michael Caplan, Department of Cellular and Molecular Physiology, Yale University School of Medicine (New Heaven, CT - USA)
  • Alexandre Mejat, AFM-Téléthon (France)
  • Olaf Riess, Institute of Medical Genetics and Applied Genomics, Medical Faculty and University Hospital, Eberhard Karls University,  (Tübingen, Germany).

Finally, we operate on the basis of a quality, ethical and supportive management and administration system. More about the Code of Ethics and Model 231 here.

Il tuo browser non è più supportato da Microsoft, esegui l'upgrade a Microsoft Edge per visualizzare il sito.